DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 88.0% from a year ago

Cash & equivalents stood at $4.87M at the end of Q1 FY2026, up 88.0% from a year earlier and down 68.9% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.

Context

  • Cash & equivalents amounted to 9.2% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +88.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.87M-68.9% QoQ
Last fiscal yearDec 2025
$15.65M+417.3% YoY
Year agoMar 2025
$2.59M+88.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+88.0%——
1 year+417.3%——
3-year CAGR+49.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
15.65M USD
Year-over-year change
+417.3%
4-year CAGR
+35.0%

Cash & Equivalents vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's Mar 2026 cash & equivalents of $4.87M is the lowest of the 7 companies compared; the peer median is $180.71M.
  • Its year-over-year change of +88.0% is the 2nd highest of 7, against a peer median of +23.5%.
  • Cash & equivalents amounts to 9.2% of total assets for DMAC, versus a peer median of 46.1%.
DMAC Competitors Peer median
Cash & Equivalents for DMAC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BIOABioAge Labs, Inc.Mar 2026$241.78M -6.1%+89.8%60.8%
DNLIDenali Therapeutics Inc.Jun 2026$201.53M +42.7%-2.0%17.4%
MAZEMaze Therapeutics, Inc.Mar 2026$198.77M -32.5%+23.7%47.4%
AKBAAkebia Therapeutics, Inc.Mar 2026$162.64M +43.5%+26.9%44.9%
PROKProKidney Corp.Mar 2026$101.9M +4.2%-39.5%34.8%
UNCYUnicycive Therapeutics, Inc.Mar 2026$37.37M +89.0%+300.4%58.0%
DMACDiaMedica Therapeutics Inc.Mar 2026$4.87M +88.0%+49.0%9.2%
Peer median (excluding DMAC) $180.71M+23.5%+25.3%46.1%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.71M4.73M4.54M3.03M15.65M
Short-term Investments40.41M28.77M48.35M41.12M44.24M
Net Receivables082K369K236K258K
Inventory00000
Other Current Assets243K00227K481K
Total Current Assets45.44M33.84M53.68M44.61M60.63M
Property, Plant & Equipment (Net)112K560K485K427K342K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0001.31M400K
Total Non-current Assets112K560K485K1.74M742K
Total Assets45.55M34.4M54.16M46.35M61.37M
Account Payables509K734K926K940K1.48M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities484K667K766K1.06M1.38M
Total Current Liabilities1.52M2.17M2.79M5.39M5.13M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities3K400K317K237K128K
Total Liabilities1.53M2.57M3.1M5.63M5.26M
Common Stock00000
Retained Earnings(82.5M)(96.18M)(115.56M)(140M)(172.77M)
Accumulated OCI(51K)(74K)6K23K50K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity44.02M31.83M51.06M40.72M56.11M
Total Debt52K469K400K340K240K
Net Debt(4.66M)(4.26M)(4.14M)(2.69M)(15.41M)

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.